Improving people’s lives with innovative technologies: Dynamic42 receives funding from the iDEA-iTECH Award

We are pleased to announce that Dynamic42 is one of the chosen companies and research groups receiving funding from of the Sanofi iDEA-iTECH Award. The initiative supports innovators in North America and Europe to develop breakthrough digital technologies and data analytics tools to create transformative solutions and processes that have the potential to improve people’s lives. Together with Sanofi, we will work to implement organ-on-chip technology for DMPK assays.

About the planned project with DMPK assays

DMPK stands for “Drug Metabolism and Pharmacokinetics” and refers to the study of the pharmacological properties of drugs. This includes e.g. research into the absorption, distribution, metabolization and excretion of a drug in the body. DMPK assays are an important part of drug development as they allow the assessment of drug efficacy and safety.

DMPK assays are used, for example, to determine optimal drug dosages or to identify adverse effects and toxicities of drugs. The implementation of organ-on-chip technology is expected to improve the precision and predictability of these assays and thus increase the efficiency of drug development. Scientists will be able to study the interactions between drugs and human cells more precisely and identify potential toxicities or efficacy problems earlier in the development process. Dynamic42s biotech chips and organ-on-chip technology will thus explicitly contribute to the improvement of investigation and analysis processes in the future.

Sanofi iDEA-iTECH Awards program

The collaboration with Sanofi in the iDEA-iTECH Awards Programme offers Dynamic42 the opportunity to expand our expertise in this field and explore new areas of application. The programme also focuses on mutual support and exchange with Sanofi experts as well as other scientists. For us, the collaboration means being able to further optimise our technology,  processes and consolidate our position as part of the drug development process.

Martin Raasch, CEO of Dynamic42, emphasises the importance of this collaboration: “Together with Sanofi, we are eager to explore new areas of application and drive possible further developments.” We look forward to the cooperation and are excited about future developments.

More interesting articles: